EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION

Their core work

EBMT is the leading European professional society for blood and marrow transplantation, representing thousands of clinicians and scientists across transplant centres. In H2020, they contribute real-world patient data from their extensive transplant registry — one of the largest in the world — to big data initiatives in hematology and cancer immunotherapy. Their role spans clinical outcome tracking, patient registry infrastructure, and helping translate advanced therapies (CAR-T, TCR-engineered cells) from lab to bedside through standardized outcome measures and real-life evidence.

What they specialise in

How they've shifted over time

EBMT's H2020 journey started with HARMONY (2017), focused on building a big data platform for classical hematological malignancies — leukemia, lymphoma, myeloma — using real-life patient registry data. By 2020-2021, their involvement shifted toward digital health outcomes, translational medicine, and business models for data platforms (HARMONY PLUS), and then into the frontier of engineered cell therapies like CAR-T and TCR (T2EVOLVE). The trajectory shows a clear move from passive data collection toward active roles in advanced therapy development and digital health infrastructure.

EBMT is expanding from its traditional registry and transplant expertise into the fast-growing field of engineered cell therapies (CAR-T/TCR), positioning itself as a bridge between clinical data and advanced therapy access.

How they like to work

EBMT participates exclusively as a consortium partner, never as coordinator — consistent with its role as a professional society that contributes domain expertise and registry data rather than leading project management. With 77 unique partners across 14 countries in just 3 projects, they operate in very large consortia (averaging ~26 partners per project). This makes them a well-connected hub in European haematology research, easy to approach as part of broad multi-stakeholder initiatives.

Despite only 3 projects, EBMT has collaborated with 77 unique partners across 14 countries, reflecting the large-consortium nature of IMI-style and big data health initiatives. Their network spans major European clinical and research centres in haematology and oncology.

What sets them apart

EBMT's transplant registry is one of the largest clinical databases in haematology worldwide, covering hundreds of transplant centres. This makes them an irreplaceable data partner for any European project needing real-world evidence on blood cancers and transplant outcomes. Few organizations can offer both the clinical network reach and the structured patient data that EBMT brings to a consortium.

Highlights from their portfolio

• HARMONY
  Flagship big data alliance in haematology involving a massive consortium, building a shared platform for real-world evidence across multiple blood cancer types.
• T2EVOLVE
  Marks EBMT's entry into engineered cell therapy (CAR-T/TCR), covering the full chain from preclinical models to GMP manufacturing and patient access.